Eisai to announce data for its epilepsy treatment at American Epilepsy Society annual meeting

23 November 2015

Japanese drug major Eisai (TYO: 4523) is set to announce key data for its Fycompa (perampanel) to treat epilepsy at the annual meeting for American Epilepsy Society (AES) in the US next month.

Neil West, vice president, Global Neurology Business Unit, Eisai EMEA, said: "These new data at AES 2015 reinforce Eisai's investment in epilepsy treatment options with the potential to improve outcomes in different patient populations. Epilepsy is a challenging condition to manage, it is therefore important that we strive to find effective treatments to support people with epilepsy."

The company has four marketed treatments for epilepsy in the Europe, the Middle East and Africa (EMEA) region, including, Fycompa, Inovelon (rufinamide), Zonegran (zonisamide) and Zebinix (eslicarbazepine acetate).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK